类固醇与角膜交联治疗溃疡:SCUT II 随机临床试验
这项由美国国立卫生研究院资助的假手术、安慰剂对照试验,在印度和美国的诊所纳入涂片和/或培养阳性的细菌性角膜溃疡且Snellen视力20/40或更差的参与者,随机接受莫西沙星+安慰剂+假交联、莫西沙星+二氟泼尼酯+假交联或莫西沙星+二氟泼尼酯+交联。结果显示,辅助局部皮质类固醇与安慰剂相比6个月视力无差异,辅助交联加皮质类固醇与单用皮质类固醇相比6个月视力无差异但瘢痕尺寸增加。
要点
- 辅助局部皮质类固醇与安慰剂相比6个月视力无差异(-0.04;95%CI,-0.18至0.09;P=0.58)。
- 辅助交联加皮质类固醇与单用皮质类固醇相比6个月视力无差异(0.04;95%CI,-0.09至0.17;P=0.62)。
- 交联加皮质类固醇与单用皮质类固醇相比6个月瘢痕尺寸增加(0.56;95%CI,0.20-0.92;P=0.02)。
核心结论
- 辅助局部皮质类固醇不优于安慰剂,辅助交联增加瘢痕尺寸,提示这些替代疗法平均而言可能不优于单用局部抗生素治疗细菌性角膜炎。
研究设计与样本
- 美国国立卫生研究院资助的假手术、安慰剂对照随机临床试验,在印度Aravind眼科医院和美国迈阿密Bascom Palmer眼科研究所的诊所进行,2020年9月至2023年10月筛查。
- 纳入涂片和/或培养阳性的细菌性角膜溃疡且Snellen视力20/40或更差的参与者,共筛查1992例涂片阳性细菌性角膜溃疡参与者,入组280例(14%;平均[SD]年龄51[16]岁;男性182例[65%])。
- 随机分为三组:局部莫西沙星0.5%+局部安慰剂+假交联、局部莫西沙星0.5%+二氟泼尼酯0.05%+假交联、局部莫西沙星0.5%+二氟泼尼酯0.05%+交联。
主要发现
- 控制基线后,辅助局部类固醇与安慰剂相比6个月视力无差异(-0.04;95%CI,-0.18至0.09;P=0.58)。
- 辅助交联加局部类固醇与单用局部类固醇相比6个月视力无差异(0.04;95%CI,-0.09至0.17;P=0.62)。
- 控制基线浸润和/或瘢痕尺寸后,辅助局部皮质类固醇与安慰剂相比6个月瘢痕尺寸无改善(-0.22;95%CI,-0.53至0.10;P=0.65)。
- 控制基线浸润和/或瘢痕尺寸后,交联加皮质类固醇与单用皮质类固醇相比6个月瘢痕尺寸增加(0.56;95%CI,0.20-0.92;P=0.02)。
- 控制浸润深度后,早期类固醇组穿孔或需治疗性穿透性角膜移植术(TPK)的风险为0.78倍(95%CI,0.27-2.24;P=0.65),交联组为0.48倍(95%CI,0.14-1.67;P=0.25)。
关键数值与推荐
- 主要结局为6个月时logMAR最佳眼镜矫正视力(BSCVA)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adjunctive topical corticosteroids and/or corneal cross-linking (CXL) have the potential to improve outcomes in bacterial keratitis. OBJECTIVE: To determine the benefit of adjunctive topical difluprednate and CXL with riboflavin in addition to topical antibiotics. DESIGN, SETTING, AND PARTICIPANTS: This was a National Institutes of Health (NIH)-funded, sham, placebo-controlled trial randomizing participants to topical moxifloxacin, 0.5%, plus topical placebo plus sham CXL, vs topical moxifloxacin, 0.5%, plus difluprednate, 0.05%, plus sham CXL, vs topical moxifloxacin, 0.5%, plus difluprednate, 0.05%, plus CXL. Between September 2020 and October 2023, participants in clinics at the Aravind Eye Hospitals in India and Bascom Palmer Eye Institute, University of Miami, in Miami, Florida, were screened for inclusion. Included participants had smear- and/or culture-positive bacterial corneal ulcers with Snellen visual acuity of 20/40 or worse. MAIN OUTCOMES AND MEASURES: The primary outcome was logMAR best spectacle-corrected visual acuity (BSCVA) at 6 months. RESULTS: Of the 1992 participants with smear-positive bacterial corneal ulcers screened, 280 participants (14%; mean [SD] age, 51 [16] years; 182 male [65%]) were enrolled. After controlling for baseline, there was no difference in 6-month VA with adjunctive topical steroids vs placebo (-0.04; 95% CI, -0.18 to 0.09; P = .58) or with adjunctive CXL and topical steroids vs topical steroids alone (0.04; 95% CI, -0.09 to 0.17; P = .62). Adjunctive topical corticosteroids also did not improve scar size at 6 months after controlling for baseline infiltrate and/or scar size (-0.22; 95% CI, -0.53 to 0.10; P = .65). CXL plus corticosteroids increased scar size compared with steroids alone after controlling for baseline infiltrate and/or scar size (0.56; 95% CI, 0.20-0.92; P = .02). There was 0.78 (95% CI, 0.27-2.24; P = .65) times the hazard of perforation or the need for therapeutic penetrating keratoplasty (TPK) in the early-steroid arm and 0.48 (95% CI, 0.14-1.67; P = .25) times the hazard of perforation or the need for TPK in the CXL arm after controlling for infiltrate depth. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that adjunctive topical corticosteroids were not superior to placebo, and adjunctive CXL had increased scar size, suggesting that these alternative therapies, on average, may not be superior to topical antibiotics alone for treatment of bacterial keratitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04097730.
引用
- Prajna NV, Lalitha P, Chandru S, et al. Steroids and Cross-Linking for Ulcer Treatment: The SCUT II Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40705354. doi:10.1001/jamaophthalmol.2025.2188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。